Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

August 10, 2017

Primary Completion Date

January 7, 2038

Study Completion Date

January 7, 2038

Conditions
MelanomaHerpetic Infection
Trial Locations (23)

3100

RECRUITING

Universitaetsklinikum Sankt Poelten, Sankt Pölten

4020

RECRUITING

Ordensklinikum Linz Elisabethinen, Linz

4052

RECRUITING

Universitaetsspital Basel, Basel

5020

TERMINATED

Landeskrankenhaus Salzburg, Salzburg

7000

TERMINATED

Kantonsspital Graubuenden, Chur

8036

RECRUITING

Medizinische Universitaet Graz, Graz

8058

RECRUITING

Universitaetsspital Zuerich, Zuerich Flughafen

15213

TERMINATED

University of Pittsburgh Medical Center, Pittsburgh

15224

RECRUITING

Allegheny Health Network, Pittsburgh

21202

RECRUITING

Mercy Medical Center, Baltimore

33076

RECRUITING

Corazon United States of America, LLC doing business as Life Clinical Trials, Coral Springs

37920

RECRUITING

University of Tennessee Medical Center, Knoxville

45242

TERMINATED

TriHealth Cancer Institute - Kenwood, Cincinnati

53792

TERMINATED

University of Wisconsin Hospital and Clinics, Madison

65109

TERMINATED

Jefferson City Medical Group PC, Jefferson City

84107

RECRUITING

Intermountain Medical Center, Murray

3109601

TERMINATED

Rambam Medical Center, Haifa

5262000

COMPLETED

Sheba Medical Center, Ramat Gan

GL53 7AN

RECRUITING

Cheltenham General Hospital, Cheltenham

SE1 9RT

RECRUITING

Guys Hospital, London

SW3 6JJ

RECRUITING

Royal Marsden Hospital, London

OX3 7LJ

RECRUITING

Churchill Hospital, Oxford

TA1 5DA

RECRUITING

Musgrove Park Hospital, Taunton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT02910557 - Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection | Biotech Hunter | Biotech Hunter